Dr. David Maberley MD, FRCS(C), MSc joins Medical
Advisor Board of Canadian Bio Med Systems Inc.
NEW YORK, MONTREAL,
SAN DIEGO, May 24, 2010 Canadian Bio Med Systems Inc.,
a subsidiary of ICBS Ltd., (OTCPK: ICBT),) , and Ocular
Therapeutics Inc., of San Diego California, announced
today that Dr David Maberley, of the Department of
Ophthalmology The University of British Columbia has
joined the Medical Advisory Board of CBMS.
David Maberley MD, FRCS(C), MSc is the director of
the Vancouver Native Health Society’s Eye Clinic.
Dr. Maberley sits on the Board of Directors of the
.
Canadian Ophthalmology Society and is also on the
Diabetic Retinopathy Guidelines Committee . He has
written Surgical and medical management of proliferative
diabetic retinopathy; Cost-effectiveness of screening
and treatment; Management of PDR and CSME; Management
of ischemic maculopathy.
Head of Vitreoretinal section of Canadian Ophthalmology
Society.
Dr. Maberley is ophthalmic director of the BC On-reserve
Telemedicine ProjectConsultant for VIHA Teleophthalmology
Program and is editor (retina) for Canadian Journal
of Ophthalmology.
Commenting on the latest member of the Medical Advisory
Board, Dr. George Tsoukas, Medical Director (CBMS),
says "Dr. Maberley is a major asset to help direct
our efforts in solving the problems of Age-related
Macular degeneration.. His experience will add greatly
to our ability to move forward."
Age-Related Macular Degeneration (AMD) is the leading
cause of blindness, worldwide, for people over 55
years of age. The incidence of AMD in persons aged
55 is 1% and increases to 15% for persons aged 80.
This debilitating disease has proven to be difficult
to treat and only a very few drugs have been developed
which have positive effects.
The drug under development by Canadian Bio Med Systems
, has a very different mode of action than the current
therapeutic products. It can be used alone or in conjunction
with these currently available products.
The product under development by CBMS, LD22-4 has
the advantage of being a very small molecule meaning
that fewer treatments will be needed compared to current
therapies, This will help reduce the pain and frequency
of injection to the patient and potentially the cost
of the treatment.
Canadian Bio Med is developing the new product in
Montreal in conjunction with its partner, Ocular Therapeutics
Inc. of San Diego, California. The drug is moving
toward human clinical trials in Canada and the United
States next year.
Canadian Bio Med Systems Inc., and Ocular Therapeutics
Inc. of San Diego California, has acquired the licensing
rights to two new potentially revolutionary drugs
in the billion dollar ophthalmic arena .
The drug for the treatment of glaucoma is being
developed by Daniel Stamer, PhD and Ronald Heimark,
PhD at the University of Arizona. Glaucoma is a prevalent
eye disease is one of the leading causes of blindness
in the world. Patient compliance is a serious problem
in glaucoma because of the frequency which conventional
medication is required. The new drug being developed
may change the paradigm of glaucoma therapy.
Eugene Levin, PhD at Torrey Pines in San Diego, California
is developing the new drug for age-related macular
degeneration (AMD). The protein in this compound is
derived from a larger, naturally occurring human protein
which will be used to control dangerous vessel growth
in the retina at the very back of the eye. The new
drug being developed is a much smaller protein than
other AMD drugs being used today which means it may
be used less frequently.
NB. This news release includes statements that constitute
forward-looking statements. Please be aware that any
such forward-looking statements are not guarantees
of future performance and involve significant risks
and uncertainties, and that actual results may vary
materially from those in the forward-looking statements
as a result of any number of factors, including the
risk factors contained in the Company's disclosure
documents.
SOURCE: Canadian Bio Med Systems Inc., ICBS Limited
CONTACT : Randy Bailey
TELEPHONE: 949- 228-4258
SOURCE: ICBS Limited www.icbs.ca
back to top
Dr. Jeffrey Olson MD to head up Canadian Bio Med Systems
Inc., as new Chairman.
NEW YORK, MONTREAL,
SAN DIEGO, April 12, 2010 Canadian Bio Med Systems
Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT),) ,
and Ocular Therapeutics Inc., of San Diego California,
announced today that Dr Jeffrey L. Olson, M.D. of
the University of Colorado has been appointed Chairman
of Canadian Bio Med Systems Inc.
Dr. Olson a retinal
surgeon is a member of the American Academy of Ophthalmology
, the Association for Research in Vision and Ophthalmology
and The American Society of Retinal Specialists. Dr.
Olson has published numerous scientific papers and
has been awarded grants from the National Institute
of Health . Dr. Olson has participated in both pre-clinical
and clinical studies for important retinal compounds.
Commenting on the Clinical Panel member, Dr. George
Tsoukas, Medical Director (CBMS), says "Dr. Olson
is the perfect person to help direct our efforts in
solving the problems of Age-related Macular degeneration,
and Glaucoma. His experience with other projects such
as this can help avoid pitfalls and speed this product
to market successfully."
Age-Related Macular
Degeneration (AMD) is the leading cause of blindness,
worldwide, for people over 55 years of age. The incidence
of AMD in persons aged 55 is 1% and increases to 15%
for persons aged 80. This debilitating disease has
proven to be difficult to treat and only a very few
drugs have been developed which have positive effects.
The drug under
development by Canadian Bio Med Systems , has a very
different mode of action than the current therapeutic
products. It can be used alone or in conjunction with
these currently available products.
The product under
development by CBMS, LD22-4 has the advantage of being
a very small molecule meaning that fewer treatments
will be needed compared to current therapies, This
will help reduce the pain and frequency of injection
to the patient and potentially the cost of the treatment.
Canadian Bio Med is developing the new product in
Montreal in conjunction with its partner, Ocular Therapeutics
Inc. of San Diego, California. The drug is moving
toward human clinical trials in Canada and the United
States next year.
The market for
products treating AMD has been estimated at over $750
million annually and growing at a rate of over 10%
yearly as the population ages.
Canadian Bio Med Systems Inc., and Ocular Therapeutics
Inc. of San Diego California, has acquired the licensing
rights to two new potentially revolutionary drugs
in the billion dollar ophthalmic arena .
The drug for the treatment of glaucoma
is being developed by Daniel Stamer, PhD and Ronald
Heimark, PhD at the University of Arizona. Glaucoma
is a prevalent eye disease is one of the leading causes
of blindness in the world. Patient compliance is a
serious problem in glaucoma because of the frequency
which conventional medication is required. The new
drug being developed may change the paradigm of glaucoma
therapy.
Eugene Levin, PhD at Torrey
Pines in San Diego, California is developing the new
drug for age-related macular degeneration (AMD). The
protein in this compound is derived from a larger,
naturally occurring human protein which will be used
to control dangerous vessel growth in the retina at
the very back of the eye. The new drug being developed
is a much smaller protein than other AMD drugs being
used today which means it may be used less frequently.
NB. This news release includes
statements that constitute forward-looking statements.
Please be aware that any such forward-looking statements
are not guarantees of future performance and involve
significant risks and uncertainties, and that actual
results may vary materially from those in the forward-looking
statements as a result of any number of factors, including
the risk factors contained in the Company's disclosure
documents.
SOURCE: Canadian Bio Med Systems Inc., ICBS Limited
CONTACT : Randy Bailey
TELEPHONE: 949- 228-4258
SOURCE: ICBS Limited www.icbs.ca
back to top
Canadian
Bio Med Systems Inc., Initiates Scientific Panel
2009-07-28 09:00
ET - News Release
NEW YORK, MONTREAL, SAN DIEGO, July 28 /PRNewswire-FirstCall/
- Canadian Bio Med Systems Inc., a subsidiary of ICBS
Ltd., (OTCPK: ICBT),) , and Ocular Therapeutics Inc.,
of San Diego California, announced today that Dr Jeffrey
L. Olson, M.D. has joined the scientific panel of
Canadian Bio Med Systems Inc.
Dr. Jeffrey Olson of the University of Colorado, a
retinal surgeon, has become a member of (CBMS's) scientific
board.
Dr. Olson is a member of the American Academy of Ophthalmology
, the Association for Research in Vision and Ophthalmology
and The American Society of Retinal Specialists. Dr.
Olson has published numerous scientific papers and
has been awarded grants from the National Institute
of Health . Dr. Olson has participated in both pre-clinical
and clinical studies for important retinal compounds.
Commenting on the Clinical Panel member, Dr. Richard
H. Keates, Chairman of Ocular Therapeutics (CBMS),
says "Dr. Olson is the perfect person to help
direct our efforts in solving the problems of Age-related
Macular degeneration. His experience with other projects
such as this can help avoid pitfalls and speed this
product to market successfully."
Age-Related Macular Degeneration (AMD) is the leading
cause of blindness, worldwide, for people over 55
years of age. The incidence of AMD in persons aged
55 is 1% and increases to 15% for persons aged 80.
This debilitating disease has proven to be difficult
to treat and only a very few drugs have been developed
which have positive effects.
The drug under development by Canadian Bio Med Systems
, has a very different mode of action than the current
therapeutic products. It can be used alone or in conjunction
with these currently available products.
The product under development by CBMS, LD22-4 has
the advantage of being a very small molecule meaning
that fewer treatments will be needed compared to current
therapies, This will help reduce the pain and frequency
of injection to the patient and potentially the cost
of the treatment.
Canadian Bio Med is developing the new product in
Montreal in conjunction with its partner, Ocular Therapeutics
Inc. of San Diego, California. The drug is moving
toward human clinical trials in Canada and the United
States next year.
The market for products treating AMD has been estimated
at over $750 million annually and growing at a rate
of over 10% yearly as the population ages.
NB. This news release includes statements that constitute
forward-looking statements. Please be aware that any
such forward-looking statements are not guarantees
of future performance and involve significant risks
and uncertainties, and that actual results may vary
materially from those in the forward-looking statements
as a result of any number of factors, including the
risk factors contained in the Company's disclosure
documents.
SOURCE Inter Canadian Business Service
Inter Canadian Business Service
CONTACT: Randy Bailey, (949) 228-4258; Source: Ocular
Therapeutics Inc. -
ICBS Ltd. www.icbs.ca
back to top
Canadian
Bio Med Systems Inc., to move AMD project to Canada
to take advantage of government funding.
NEW YORK, MONTREAL,
SAN DIEGO, September 28, 2009 - Canadian Bio Med Systems
Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT),) ,
and Ocular Therapeutics Inc., of San Diego California,
announced today that the company will be moving the
AMD project to Canada to take advantage of the R&D
funding by both the Canadian and provincial governments.
Age-Related Macular Degeneration (AMD) is the leading
cause of blindness, worldwide, for people over 55
years of age. This debilitating disease has proven
to be difficult to treat and only a very few drugs
have been developed which have positive effects.
The drug under development by Canadian Bio Med Systems
, has a very different mode of action than the current
therapeutic products. It can be used alone or in conjunction
with these currently available products.
“We have already demonstrated in several different
animal models that angiogenesis is dramatically suppressed
in the presence of LD22-4,” said Eugene Levin,
Ph.D., He added, “The proposed method of administration
of LD22-4, intravitreal injection, is commonly used
to administer ophthalmic drugs and generally accepted
by patients facing the prospect of blindness and other
serious back of the eye complications. However we
believe that our therapy can be adopted to offer a
less invasive method of administration that may have
a competitive advantage over one administered by intravitreal
injection.”
LD22-4 is currently in Phase One studies and a patent
application has been filed for the therapeutic use
of this product.
The market for products treating AMD has been estimated
at over $2 billion annually and growing at a rate
of over 10% yearly as the population ages.
The Research & Development tax credit programs
in Canada, offer the company the ability to receive
back up to 75% of the costs involved with the development
of the AMD drug. The company has had preliminary talks
with a Federal government representative and expects
to apply for the R&D grant this fall.
SOURCE: Canadian Bio Med Systems Inc., ICBS Limited
CONTACT : Randy Bailey
TELEPHONE: 949- 228-4258
SOURCE: ICBS Limited www.icbs.ca
back to top
|
